Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/577—Malvaceae (Mallow family)
  • A61K36/5777—Theobroma, e.g. cocao or cocoa
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents

Definitions

• This invention relates to a cocoa extract and to its uses.
• the invention relates to uses for cocoa extracts in the treatment or alleviation of obesity.
• chocolate and cocoa are popularly claimed to have a plethora of positive effects, including stimulant, relaxant, euphoriant, aphrodisiac, tonic and antidepressant properties.
• the scientific basis for these claims has been elusive.
• depression may in some individuals lead to a craving for sweet foods, and people may receive a transitory uplift in mood from the pleasure of consuming chocolate or from relief of hypoglycemia due to consumption of the sugar in the chocolate.
• the various chemicals in chocolate (other than sugar) suggested to have potentially psychoactive or mood altering effects are generally not present at pharmacologically effective levels.
• Cocoa for the production of chocolate is made from the dried and partially fermented seeds of the cacao tree.
• the harvested cacao pods are opened, the pulp and cocoa beans are removed, and the rind is discarded.
• the pulp and beans are then piled in heaps, placed in bins, or laid out on grates for usually 6-7 days, during which time the thick pulp liquifies as it ferments.
• the fermented pulp trickles away, leaving the cocoa beans behind to be collected, dried and further processed to make cocoa butter and cocoa powder.
• the product is treated with alkali to reduce the acidity of the powder. Fermentation is important for the quality and flavor of the beans, which originally have a strong bitter taste.
• Unfermented or underfermented cocoa beans have a flavor similar to raw potatoes, are very susceptible to mildew and fungal growth, and therefore are not used in the manufacture of chocolate for food consumption.
• the cocoa bean without its shell is known as a "cocoa nib".
• Cocoa is known to contain polyphenols and other biologically active compounds such as xanthines, including theobromine and caffeine.
• Obesity is a condition in which the natural energy reserve, stored in the fatty tissue of humans and other mammals, is increased to a point where it is associated with certain health conditions or increased mortality. Although obesity is an individual clinical condition, it is increasingly viewed as a serious and growing public health problem.
• Cocoa extracts containing polyphenols have been proposed for a number of uses.
• WO 96/010404 describes cocoa extracts containing proanthocyanidins that are said to be anti-neoplastic.
• US 7,122,574 discloses polyphenol-containing cocoa extracts that can be used for treating hypertension.
• WO 03/079998 states that cocoa extracts containing polyphenols can be used in the treatment of diseases involving defective gap junctional communication.
• US 6,927,280 discloses a cocoa albumin and its uses.
• US 7,115,285 relates to a composition, comprising theobromine or a salt thereof, for suppressing appetite and cravings for substances such as nicotine, coffee, sweets or chocolate while improving energy and enhancing mood.
• WO 2007/042745 discloses a composition comprising chocolate which is enhanced with theobromine and reviews the active components in chocolate, stating that cocoa contains a number of chemical substances whose influence on human and/or animal physiology is not fully understood, including phenylethylamine and tyramine which act as neurotransmitters and may effect mood swing by causing an emotional high, which can be associated with a feeling of alertness and contentment.
• US 7,122,574 discloses a polyphenol-containing cocoa extract and numerous applications for it, including an effect on satiety.
• the extracts were made from defatted cocoa material.
• WO 98/09533 describes cocoa components having enhanced levels of cocoa polyphenols.
• US 2004/0096566 relates to a method for obtaining cocoa bean polyphenol extracts.
• US 2004/0005347 relates to a composition and method for treating several disorders including obesity, that involves the use of cocoa or one of its active components together with a dopamine D2 receptor agonist.
• compositions comprising dietary fibre extracted from cocoa bean husks.
• the compositions are stated as being useful in the treatment of metabolic disorders.
• EP-A- 1609466 states that a composition in tablet form comprising cinnamon leaf oil, ginger extract, oleoresin or oil, turmeric extract oil and/or oleoresin, cocoa extract, citric acid, citrus essential oils, and a white kidney bean protein fraction with alpha amylase inhibitory activity, can be used for treating overweight humans and animals.
• the cocoa extract contains 6% theobromine but it is not clear how it is produced.
• US 2006/0210653 relates to compositions for increasing a person's natural metabolic rate.
• a cocoa extract is one of the many possible extracts described but there is no indication as to how it is produced.
• US 2006/0204599 relates to a dietary supplement derived from Acacia for maintaining weight loss.
• US 2006/0134230 discloses a weight loss composition comprising several extracts, including a cocoa extract.
• the cocoa extract contains theobromine but there is no indication as to how it is produced.
• WO 02/14251 describes a method for obtaining cocoa bean polyphenol extracts by solvent extraction of fresh cocoa beans.
• the extracts have cosmetic, food and therapeutic uses and may contain increased levels of beta-sitosterol.
• WO 2007/082703 relates to the use of cocoa polyphenols, which may be produced by the method described in WO 02/14251 , in beer production.
• FR-A-2885050 describes a slimming cosmetic and/or pharmaceutical composition comprising a cocoa extract containing polyphenols for the treatment of adipocytes of the skin.
• compositions that are useful in the treatment or alleviation of obesity particularly compositions that are derived from natural products.
• compositions having these benefits that can be readily incorporated into formulations for oral consumption.
• the compositions for incorporation into foods and beverages are desirably readily dispersible and impart a good appearance to the product, in terms of colour and/or texture.
• a cocoa extract obtainable by the extraction of non-defatted cocoa beans which have not been fermented or have been allowed to ferment for no more than three days, having a polyphenol content of more than 25% by weight, for use in the treatment or alleviation of obesity.
• the invention provides the use of a cocoa extract obtainable by the extraction of non-defatted cocoa beans which have not been fermented or have been allowed to ferment for no more than three days, having a polyphenol content of more than 25% by weight, in the manufacture of a medicament for use in the treatment or alleviation of obesity.
• the invention provides a method for the treatment or alleviation of obesity, comprising administering an effective amount of a cocoa extract obtainable by the extraction of non-defatted cocoa beans which have not been fermented or have been allowed to ferment no more than three days, having a polyphenol content of more than 25% by weight.
• the extracts according to the invention prepared from non- defatted cocoa beans which have not been fermented or have been fermented for a short time, such as less than three days, have advantages in terms of their effect in treating obesity. This was surprising. Most of the known cocoa extracts that are asserted as having physiological effects are derived from defatted and/or fermented beans, which are often also roasted.
• the extract of the invention is typically a brown-coloured, free-flowing powder. Usually, the extract will have no noticeable odour.
• the extract of the invention preferably has a polyphenol content of at least 27% by weight, more preferably at least 30% by weight, even more preferably at least 40% by weight, such as at least 45% by weight.
• the upper limit for the polyphenol content is typically about 70% by weight.
• preferred amounts of polyphenol include from 30% to 70%, from 35% to 70%, from 40% to 70%, from 45% to 65% and from 45% to 60%, the percentages being by weight of the extract.
• the percentages of polyphenols are preferably expressed as gallic acid equivalents, according to the Folin-Ciocalteu method (e.g., as described in Singleton VL, Orthofer R, Lamuela-Raventos RJVl. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. Meth Enzymol 1999; 99: 152-178).
• Polyphenols in the extracts of the invention typically comprise monomers and oligomers.
• the extracts of the invention comprise up to 10% by weight of each of monomers, dimers, trimers, tetramers, pentamers, hexamers, heptamers, octamers, nonamers and decamers, and higher oligomers in an amount of up to 15% by weight.
• extracts of the invention comprise, by weight of the extract, 5-10% monomers (preferably including at least 5% epicatechin), 5- 10% dimers, 5-10% trimers, 2-8% tetramers, 2-8% pentamers, 2-8% hexamers, 0.5-5% heptamers, 0.1-4% octamers, 0.1-3% nonamers and 0.05-2% decamers, and 5-12% higher oligomers.
• Extracts of the invention may contain xanthines (preferably methylxanthines), such as caffeine and theobromine.
• Caffeine may be present together with theobromine, typically at a weight ratio of theobromine to caffeine in the range of from 20: 1 to 5:1.
• the theobromine content is at least 5% by weight, and preferably from 5 to 11% by weight.
• the composition preferably has a weight ratio of from 7:1 to 12:1 polyphenol:theobromine.
• the extract may be treated, for example with supercritical carbon dioxide, to lower the theobromine content and the content of other xanthines that may be present.
• the extract has a theobromine content of less than 5% by weight, such as less than 4.5% by weight, for example from 0.1 to 4% by weight.
• the extracts of the invention are prepared from cocoa beans that are non-defatted and have not been fermented or have been allowed to ferment for no more than three days.
• the cocoa beans will typically not have been roasted.
• the cocoa beans that are used as the starting material for the production of the extracts of the invention are very different from the cocoa beans that are used to produce cocoa powder and chocolate.
• the extracts are prepared from cocoa nibs which are deshelled cocoa beans that are unfermented and non-roasted.
• the cocoa beans are preferably obtained by a process that comprises: harvesting and hulling cocoa beans; preventing fermentation of the beans or allowing the beans to ferment for no more than three days (more preferably less than two days, even more preferably less than one day) before halting the fermentation process by drying.
• the fat content of the non-defatted cocoa beans, or of the cocoa nibs, that are used in the invention is typically greater than 30% by weight, more preferably greater than 35% by weight, even more preferably greater than 40% by weight, such as greater than 45% by weight; for example, greater than 50% by weight.
• Extracts of the invention are preferably obtainable by solvent extraction of the cocoa beans.
• the solvent is preferably selected from Cl to C6 alcohols or Cl to C6 ketones, and mixtures thereof, optionally in admixture with water, such as, for example, ethanol, acetone, 2-butanol, 2-propanol and mixtures thereof, optionally in admixture with water.
• a particularly preferred solvent comprises a mixture of water and acetone in a weight ratio of wateracetone of from 1 :1 to 1 :9.
• solvent extraction is carried out using a counter current process for a time and at a temperature to achieve the desired degree of extraction, typically from one hour to 2 days at from 20 to 60 0 C.
• the liquid solvent extract is evaporated to remove a part of the solvent and then spray dried.
• the extract powder is preferably agglomorated in a fluidised bed.
• the xanthine (and theobromine) content of the extract may be reduced by extraction with super-critical carbon dioxide after the solvent has been removed.
• Extracts of the invention preferably comprise less than 2% by weight phenylethylamine.
• Extracts of the invention may comprise other components derived from the cocoa beans such as protein and sugars.
• the extracts comprise from 15 to 40% by weight protein, such as from 20 to 30% by weight protein.
• the extracts may comprise from 2 to 12% by weight sugars, such as from 4 to 10% by weight sugars.
• the extracts of the invention comprise cocoa fats.
• fats as used in this context includes lipid material in cocoa beans such as sterols, lipids and phospholipids, as well as mono-glycerides and di-glycerides.
• these one or more components of the cocoa fats contribute to the beneficial physiological effects of the extracts of the invention.
• Preparing the extracts of the invention from cocoa beans which have not been defatted or fermented for any substantial length of time increases the amounts of these fat components compared to extracts from defatted beans or beans that have been fermented.
• the extracts of the invention comprise from 0.1 to 10% by weight of cocoa fats, such as from 0.2 to 8%, or from 0.3 to 7%, or from 0.5 to 5%, or from 0.7 to 3%, by weight of cocoa fats.
• cocoa fats are non-triglyceride lipids.
• An example of a preferred extract of the invention comprises:
• Another extract of the invention comprises by weight 50-60% polyphenols, 7-10% theobromine, and less than 2% phenylethylamine.
• this extract may comprise by weight 54-58% polyphenols, 8-9% theobromine, and 0.5-1.5% phenylethylamine.
• the fat content is preferably no more than 1% and/or the sugar content is no more than 3%.
• One or more extracts of the invention may be admixed to form a mixed extract composition.
• the extracts are used in the invention to treat or alleviate obesity (preferably in a human).
• obesity is used herein to refer to obese and overweight condition. These conditions may be determined by measuring body mass index, waist to hip ratio or body fat.
• the extracts of the invention do not rely for their action on a satiety effect or on appetite suppression or on an anti-depressive or mood enhancement effect. Instead, and without wishing to be bound by theory, it is believed that the extracts have the effect of increasing metabolism and/or the rate at which fat is burned by the subject. Therefore, the invention provides the treatment or alleviation of obesity by increasing metabolism and, in another aspect, relates to the use of the extracts for increasing metabolic rate. Extracts and compositions of the invention preferably do not contain a dopamine D2 receptor agonist added to the cocoa extract (e.g., from a plant extract other than a cocoa extract).
• the extracts of the invention are preferably formulated for oral consumption.
• the extract may be provided as part of a foodstuff or confectionery product.
• the extract will be included in the foodstuff or confectionery product in an amount of from 0.1% to 50% by weight, such as from 0.5% to 10% by weight.
• Foodstuffs and confectionery products include, for example, those having a fat continuous phase as well as those having a water continuous phase. Foodstuffs include foods and beverages.
• Beverages include those adapted for consumption hot or cold. Beverages include one or more additives selected from sweeteners, flavouring agents, colouring agents, stabilisers and preservatives. Beverages will typically comprise from 50% to 99% water. Beverages will typically comprise the extracts of the invention dispersed and/or suspended therein. The extract of the invention may be formulated as a powder which can be converted to a beverage on the addition of water and mixing.
• Foodstuffs typically comprise one or more of protein, fat and carbohydrate.
• Foodstuffs include dairy products and confectionery products.
• a preferred foodstuff comprises vegetable fat and/or cocoa butter.
• Particularly preferred foodstuffs include chocolate and chocolate-like products comprising cocoa solids and sugar.
• the extracts of the invention may be included in conventional chocolate or chocolate-like products in amounts of from 0.1% to 50% by weight, such as from 0.5% to 25% by weight.
• Chocolate or chocolate-like products preferably comprise one or more components selected from the group consisting of cocoa materials, sugars, sugar substitutes, milk powders, fat, emulsifier, flavouring agents and mixtures thereof.
• the cocoa materials are selected from cocoa powder, cocoa mass, cocoa liquor, cocoa butter and mixtures thereof.
• Milk powders include, for example, skimmed milk powder, whey powder and derivatives thereof, full cream milk powder and mixtures thereof.
• Suitable sugars include sucrose, fructose, glucose and dextrose and mixtures thereof (with sucrose being preferred).
• Sugar substitutes preferably include inulin, dextrin, isomaltulose, polydextrose and maltitol and mixtures thereof.
• Fats include butter fat or fractions thereof, palm oil or fractions thereof, coconut or fractions thereof, palm kernel oil or fractions thereof, liquid oils (for example, sunflower oil and/or rapeseed oil), interesterified mixtures of the above fats or fractions or hardened components thereof, or mixtures thereof.
• Emulsifiers include lecithin, fractionated lecithin and PGPR or mixtures thereof.
• Flavouring agents include vanilla and caramel or mixtures thereof.
• Chocolate and chocolate-like products may comprise one or more food additives such as biscuit, nuts (whole or pieces), crispies, sponge, wafer or fruit, such as cherries, ginger and raisins or other dried fruit. These additives are normally embedded in the product.
• the extract may be provided as a pharmaceutical composition or supplement.
• compositions are preferably in the form of tablets, pills, capsules, caplets, multiparticulates including: granules, beads, pellets and micro- encapsulated particles; powders, elixirs, syrups, suspensions and solutions.
• Pharmaceutical compositions will comprise a pharmaceutically acceptable diluent or carrier.
• Pharmaceutical compositions are preferably adapted for administration parenterally (e.g., orally).
• Orally administrable compositions may be in solid or liquid form and may take the form of tablets, powders, suspensions and syrups.
• the compositions comprise one or more flavouring and/or colouring agents.
• Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy.
• the pharmaceutial compositions of the invention may contain 0.1-99% by weight of the extract.
• Supplements may, for example, comprise the extract in liquid form (e.g., as a solution, dispersion or suspension) and/or encapsulated in a capsule.
• Supplements (which term includes dietary and nutritional products) may take the form of a soft gel or a hard capsule comprising an encapsulating material, preferably selected from the group consisting of gelatin, glycerol, starch, modified starch, starch derivatives such as glucose, sucrose, lactose and fructose.
• the encapsulating material may optionally contain cross-linking or polymerizing agents, stabilizers, antioxidants, light absorbing agents for protecting light-sensitive fills, preservatives and the like.
• the amount of the extract in the food supplements is from 1 mg to 1000 mg (such as from 50 to 500 mg).
• the term "effective amount" refers to the amount of an extract or composition which is effective, upon single or multiple dose administration to a patient, in treating obesity.
• An effective amount of the extracts of the invention is in general, about 0.1 to 20 g/day, e.g., 1-10 g/day for an adult human, most preferably from 0.5 to 5 g/day.
• the daily dose may be administered once per day, or in divided doses.
• the extract can be administered orally, transdermally or rectally, preferably orally.
• An effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances.
• a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease or disorder involved; the degree of or involvement or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
• the extract was prepared by extraction of cocoa nibs (deshelled cocoa beans unfermented and non-roasted) in a counter-current process with the use of a 70/30 mixture of acetone/water.
• the liquid extract is evaporated and then spray-dried.
• the extract powder is agglomorated in a fluidised bed.
• the extract had the following composition (% by weight):
• the polyphenol content (as % by weight of total polyphenols) was as follows:
• TG total gain
• TFI total feed intake
• CPT-I carnitine palmitoyltransferase
• a defatted polyphenols extract was prepared as follows.
• a cocoa polyphenolic extract of the invention was prepared from non-defatted cocoa beans generally as described in Example 1 but having a comparable polyphenol content to the extract from defatted beans.
• the cocoa polyphenolic extract of the invention (referred to as AP48) and the cocoa polyphenolic extract from defatted cocoa beans (referred to as M48) were both orally administered at the dose of 48 mg/kg BW for 4 weeks to obesity induced female Sprague-Dawley rats.
• Body weight and final body fat mass were determined before and after treatment and the results were as follows.

Landscapes

• Health & Medical Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Alternative & Traditional Medicine (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Organic Chemistry (AREA)
• Obesity (AREA)
• Child & Adolescent Psychology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicines Containing Plant Substances (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Confectionery (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (3)

Applications Claiming Priority (4)

Publications (1)

Family

ID=38739239

Family Applications (1)

Country Status (5)

Cited By (6)

Families Citing this family (16)

Citations (5)

Family Cites Families (60)

• 2007
  • 2007-10-08 GB GBGB0719542.3A patent/GB0719542D0/en not_active Ceased
• 2008
  • 2008-04-24 WO PCT/EP2008/003322 patent/WO2008131910A1/en not_active Ceased
  • 2008-04-24 JP JP2010504544A patent/JP5450383B2/ja not_active Expired - Fee Related
  • 2008-04-24 US US12/597,569 patent/US8709503B2/en active Active
  • 2008-04-24 EP EP08735382A patent/EP2142201A1/en not_active Withdrawn

Patent Citations (5)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events